Navin Fluorine International (532504) Q1 24/25 earnings summary

Executive summary

• Q1 FY25 consolidated revenue rose 7% year-over-year to Rs. 523.7 crore, driven by strong HPP performance and new R-32 capacity sales, while operating EBITDA declined 12% to Rs. 100.4 crore with a margin of 19.2%.

• Profit after tax declined 17% YoY to Rs. 51.2 crore, mainly due to higher depreciation from new CapEx; total comprehensive income fell 16% YoY.

• Specialty chemicals and CDMO segments faced headwinds from global inventory rationalization and delayed purchasing decisions, with revenues declining 30% and 13% YoY, respectively.

• Multiple capacity expansion projects are progressing on schedule, with significant CapEx investments in agro, AHF, cGMP4, and R-32 plants.

• Leadership transition with a new Managing Director, bringing extensive industry experience.

Financial highlights

• Q1 FY25 consolidated revenue reached Rs. 523.68 crore, up 7% YoY; standalone revenue was Rs. 376.28 crore, up 7% YoY.

• Operating EBITDA was Rs. 100.4 crore, down 12% YoY, with margins at 19.2% versus 23.3% last year.

• Profit after tax stood at Rs. 51.2 crore, a 17% decline YoY; standalone PAT was Rs. 50.02 crore, down from Rs. 63.01 crore YoY.

• Operating cash flow for the quarter was Rs. 107 crore, supported by improved working capital management.

• Net debt to equity at 0.38x as of June 2024.

Outlook and guidance

• Expect gradual margin improvement through FY25, with a stronger second half anticipated for both specialty and CDMO segments.

• Firm orders secured for new agro specialty capacity, with commercial production set for September 2024.

• CDMO business expected to surpass FY24 performance, with a $100 million revenue aspiration by FY27.

• Peak revenue guidance for new Rs. 540 crore CapEx remains unchanged, targeting full ramp-up by FY27.

• AHF capex of Rs. 450 crore and additional R32 capacity capex of Rs. 84 crore are on schedule for commissioning by end FY25/early FY26 and Feb 2025, respectively.